Drug Trial Radar · NCT04109222
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Sep 30, 2019
Primary completion
Dec 10, 2019
Study completion Dec 10, 2019
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 83 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study was to provide sera (collected from participants before vaccination \[Blood Sample 1\] and after final vaccination \[Blood Sample 2\]) to the Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines.
Conditions
- Influenza
Interventions
Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulationBiological
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Fluzone High-Dose vaccine, 2019-2020 formulationBiological
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Aged 6 Months to < 9 Years Who Provided Serum Samples for Analysis: Groups 1 and 2Time frame: Visit 1 (Day 0; pre-vaccination) and 28 days post-final vaccination at Visit 2/Visit 3
- Number of Participants Aged >= 65 Years Who Provided Serum Samples for Analysis: Group 3Time frame: Visit 1 (Day 0; pre-vaccination) and 21 days post-vaccination (Visit 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 8400002
Bardstown, Kentucky
Investigational Site Number 8400001
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.